<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368757</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_CMML 1</org_study_id>
    <secondary_id>2009-017147-33</secondary_id>
    <nct_id>NCT01368757</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Patients With Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide&#xD;
      in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started&#xD;
      once an optimal dose has been found. The primary endpoint will concern the efficacy of&#xD;
      lenalidomide in patients with CMML according to the WHO diagnostic criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>2 years</time_frame>
    <description>This is a phase I/II, open-label, dose-escalation study of lenalidomide in patients with CMML. In phase I of the study the primary purpose is to determine the MTD. The purpose of phase II is to determine the response rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and seriousness of adverse events to evaluate safety and tolerability</measure>
    <time_frame>4 years</time_frame>
    <description>For both phases (phase I and II), secondary objectives are to evaluate safety, tolerability, efficacy and analysis of molecular markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving transfusion independence</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients achieving cytogenetic response</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II; Cytogenetic response assessment requires 20 analyzable metaphases using conventional cytogenetic techniques, FISH may be used an a supplement to follow a specifically defined cytogenetic abnormality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revlimid</intervention_name>
    <description>Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients&#xD;
The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.&#xD;
Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen.</description>
    <other_name>lenalidomide</other_name>
    <other_name>lenalidomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. CMML according to the WHO diagnostic criteria.&#xD;
&#xD;
          2. Understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          3. Age &gt;=18 years at the time of signing the informed consent form.&#xD;
&#xD;
          4. Able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          5. All previous cancer therapy must have been discontinued at least 4 weeks prior to&#xD;
             treatment in this study. Patients carrying a somatic mutation involving the platelet&#xD;
             derived growth factor receptor beta (PDGFRB) can be included if standard treatment&#xD;
             with imatinib failed.&#xD;
&#xD;
          6. ECOG performance status of &lt;= 2 at study entry.&#xD;
&#xD;
          7. Laboratory test results within these ranges:&#xD;
&#xD;
               -  Creatinine clearance &gt; 30ml/min&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) &lt;= 2.5 x ULN&#xD;
&#xD;
          8. Disease free of prior malignancies for &gt;= 5 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast.&#xD;
&#xD;
          9. Female subjects of childbearing potential must:&#xD;
&#xD;
               -  Understand the study drug is expected to have a teratogenic risk&#xD;
&#xD;
               -  Agree to use two effective contraception&#xD;
&#xD;
         10. Male subjects must&#xD;
&#xD;
               -  Agree to use condoms&#xD;
&#xD;
               -  Agree not to donate semen&#xD;
&#xD;
         11. All subjects must&#xD;
&#xD;
               -  Agree to abstain from donating blood&#xD;
&#xD;
               -  Agree not to share study drug with another person&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking lenalidomide).&#xD;
&#xD;
          3. Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          4. Use of any other experimental drug or therapy within 28 days of baseline.&#xD;
&#xD;
          5. Known hypersensitivity to thalidomide.&#xD;
&#xD;
          6. The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs.&#xD;
&#xD;
          7. Any prior use of lenalidomide.&#xD;
&#xD;
          8. Concurrent use of other anti-cancer agents or treatments.&#xD;
&#xD;
          9. Known positive for HIV or infectious hepatitis, type A, B or C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Thaler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Wels-Grieskirchen GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonja Burgstaller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Wels-Grieskirchen GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus d. Barmherzigen Schwestern Linz, Interne I</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH, 1. Interne</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung</name>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik f. Innere Medizin Graz, Klinische Abteilung f. Hämatologie</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch, Interne E</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik der PMU Salzburg, UK f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUW/ AKH Wien Univ. Klinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus, 3. Med. Abtlg. Für Hämatologie und Onkologie</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Richard Greil</name_title>
    <organization>Arbeitsgemeinschaft medikamentoese Tumortherapie</organization>
  </responsible_party>
  <keyword>Chronic myelomonocytic leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 21, 2019</submitted>
    <returned>April 17, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

